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Et-2-(4-Cl-Ph) 2.5 11
Pr-3-(3-Cl-Ph) 2.7 12
Pr-3-OH 2.8 13
Pr-3-CF 3 9.8 14 Me-benzofuran-2-yl 2.4 15
Me-(4-NH 2 CO-oxazol-2-yl) 3.6 16
Me-(4-MeOCO-oxazol-2-yl) 12 NA = Not active at 20 µM Software Inc. The receptor file containing the structural information of the β-exosite was generated using a previously reported crystal structure of the BoNT/A LC (PDB ID: 1XTG) 3 and the Make Receptor program.
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General Procedure for Indole Alkylation and tert-butyl Ester Deprotection. The corresponding tert-butyl indolylpicolinate (0.03 mmol, 1a-r) and alkyl iodide (1.5 eq) or alkyl bromide (4 eq) were dissolved in dry DMF. Cs 2 CO 3 (29 mg, 3 eq for iodide; 59 mg, 6 eq for bromide) was added and the mixture was stirred at 80 °C for 1 h (iodide) or 18 h (bromide) in a sealed vial under inert atmosphere. The resulting suspension was allowed to cool, filtered and purified by pTLC with 1:2 EtOAc/hexane as an eluent, yielding the corresponding tertbutyl N-alkyl indolylpicolinate typically as a colorless oil. Tert-butyl deprotection proceeded by stirring the ester in 1 mL 1:1 DCM/TFA for 2 h and evaporating the solvent to quantitatively produce the final picolinic acid as a TFA salt (2-16, 22) typically as an orange oil. Product masses and yields are reported for tert-butyl esters for higher accuracy.
tert-butyl 5-(1H-indol-2-yl)picolinate (1a)
. The title compound was prepared from indole-2-boronic acid pinacol ester using the general Suzuki coupling procedure as a yellow solid (53 mg, 58% yield). 1 57, 146.76, 146.05, 137.73, 133.51, 132.33, 128.33, 124.81, 122.84, 120.65, 119.90, 111.61, 101.73, 81.29, 27.79 67, 147.72, 146.32, 136.62, 134.87, 131.74, 129.67, 129.15, 124.59, 122.78, 119.06, 119.00, 111.33, 110.16, 81.35, 27.80, 9. 49, 147.24, 146.34, 138.34, 134.56, 132.83, 130.08, 126.93, 124.76, 124.66, 123.56, 119.42, 110.75, 99.66, 81.40, 27.77 63, 163.74, 149.79, 149.60, 143.24, 138.20, 136.39, 129.36, 126.32, 125.24, 124.84, 123.73, 122.26, 116.28, 111.89, 83.44, 28.22 tert-butyl 5- (3-ethyl-1H-indol-2-yl) picolinic acid (1f). To a solution of 3-acetylindole (80 mg, 0.50 mmol), Pd/C 5 wt % (106 mg) in cyclopentyl methyl ether (0.5 mL) was added sodium hypophosphite monohydrate (159 mg, 1.5 mmol) and hypophosphorous acid (1 mL, 50% in water), and the mixture was heated at 100 °C for 4 h. The cooled mixture was partitioned between DCM and water and the organic layer was collected, dried over MgSO 4 and concentrated. The crude product was purified by pTLC using 1:4 EtOAc/hexane as an eluent to yield 3-ethylindole (30 mg, 41%). The title compound was prepared using the general procedure for the two step, one pot C-H borylation/Suzuki coupling from 3-ethyl indole (0.08 mmol), yielding the product as a white solid (5 mg, 16% over two steps 21, 148.49, 147.58, 136.95, 135.17, 132.19, 129.38, 128.87, 124.98, 123.52, 120.07, 119.66, 118.62, 111.38, 82.62, 28.28, 17.99, 15. 24, 149.44, 149.00, 147.50, 144.39, 140.47, 136.00, 135.39, 124.87, 124.79, 122.54, 118.74, 116.35, 115.26, 112.97, 81.87, 27.73 49, 147.15, 146.23, 136.11, 135.18, 132.70, 130.25, 129.39, 124.79, 124.37, 122.73, 119.65, 113.16, 101.22, 81.38, 27.77 50, 147.04, 146.16, 138.00, 134.66, 132.53, 130.30, 127.29, 127.09, 124.79, 122.05, 120.33, 111.08, 101.79, 81.36, 27.78 313.1346. 58, 146.58, 145.93, 137.48, 132.81, 132.16, 130.87, 129.69, 128.48, 124.81, 122.98, 119.85, 109.20, 100.54, 81.25, 27.79, 18.56 309.1598. 73, 153.44, 145.95, 144.00, 139.45, 132.59, 131.90, 131.33, 124.44, 124.21, 119.70, 104.84, 99.77, 99.55, 82.26, 55.36, 27.85 20, 157.72, 150.04, 149.24, 147.84, 138.94, 137.08, 136.27, 134.93, 133.80, 128.68, 128.08, 13 127.70, 123.91, 123.16, 121.54, 113.65, 112.37, 101.04, 82.41, 70.57, 27. 56, 138.02, 137.50, 132.06, 130.78, 130.03, 129.48, 128.40, 127.07, 125.37, 124.30, 122.74, 119.10, 110.61, 97.55, 60.98, 14.22 
tert-butyl 5-(4-methyl-1H-indol-2-yl)picolinic acid (1m

tert-butyl 5-(4-methoxy-1H-indol-2-yl)picolinate (1n)
.
tert-butyl 5-(6-(benzyloxy)-1H-indol-2-yl)picolinate (1o
300.0791, obs. 300.0707.
ethyl 4-(4-chloro-1H-indol-2-yl) benzoate (1r). The title compound was prepared from 4-chloroindole-2-boronic acid pinacol ester (0.12 mmol) and ethyl 4-bromobenzoate (0.12 mmol) using the general Suzuki coupling procedure as a white solid (33 mg, 92% yield 5- (1-ethyl-1H-indol-2-yl) picolinic acid (2a) . The title compound was prepared from 1a (0.015 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (4.5 mg, 88% 
5-(1-ethyl-3-methyl-1H-indol-2-yl)picolinic acid (2b)
. The title compound was prepared from 1b (0.021 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (3.3 mg, 47% 145.66, 143.57, 142.37, 137.77, 134.70, 129.76, 128.71, 126.33, 124.16, 120.37, 120.03, 114.24, 110.30, 39.34, 15.24, 9. 
5-(4-chloro-1-ethyl-1H-indol-2-yl)picolinic acid (2c)
. The title compound was prepared from 1c (0.023 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (4 mg, 49% 5- (1-ethyl-5-fluoro-1H-indol-2-yl) picolinic acid (2d). The title compound was prepared from 1d (0.021 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (1 mg, 14% 
5-(1-propyl-1H-indol-2-yl)picolinic acid (3a)
. The title compound was prepared from 1a (0.015 mmol) and 1-iodopropane using the standard alkylation/deprotection procedure to yield the product as an orange oil (3.8 mg, 71% 22, 151.16, 148.41, 138.50, 137.21, 132.85, 131.68, 128.58, 124.54, 122.74, 119.65, 119.40, 111.38, 110.04, 45.85, 23.47, 11.40 
5-(3-methyl-1-propyl-1H-indol-2-yl)picolinic acid (3b)
. The title compound was prepared from 1b (0.021 mmol) and 1-iodopropane using the standard alkylation/deprotection procedure to yield the product as an orange oil (5.6 mg, 76%). Hz, 3H). 13 C NMR (151 MHz, CDCl 3 ) δ 163. 72, 146.63, 143.05, 142.73, 137.97, 134.58, 130.55, 128.55, 16 125.80, 123.88, 120.23, 119.91, 113.60, 110.44, 46.14, 23.51, 11.34, 9. 5- (1-butyl-1H-indol-2-yl) picolinic acid (4a). The title compound was prepared from 1a (0.015 mmol) and 1-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (2.9 mg, 55% 138.25, 136.99, 136.65, 132.11, 128.14, 124.68, 122.74, 121.15, 120.42, 110.42, 104.45, 44.24, 32.33, 20. 5- (1-butyl-3-methyl-1H-indol-2-yl) picolinic acid (4b). The title compound was prepared from 1b (0.016 mmol) and 1-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (2.7 mg, 46%). 74, 146.67, 143.09, 142.62, 137.89, 134.50, 130.53, 128.55, 125.76, 123.84, 120.19, 119.89, 113.56, 110.40, 44.32, 32.25, 20.09, 13.68, 9. 5- (1-butyl-4-chloro-1H-indol-2-yl) picolinic acid (4c). The title compound was prepared from 1c (0.031 mmol) and 1-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (5.7 mg, 48%). 145.51, 143.53, 141.07, 139.44, 134.80, 134.18, 126.88, 126.83, 126.04, 124.26, 120.57, 109.37, 104.69, 44.81, 32.29, 20.03, 13. 5- (1-butyl-5-fluoro-1H-indol-2-yl) picolinic acid (4d). The title compound was prepared from 1d (0.021 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (4 mg, 42% 5- (1-butyl-3-formyl-1H-indol-2-yl) picolinic acid (4e). The title compound was prepared from 1e (0.012 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (3.2 mg, 70% 163.78, 149.59, 147.13, 144.70, 140.66, 137.06, 130.05, 125.54, 125.22, 124.18, 123.92, 122.50, 117.18, 110.68, 44.48, 32.08, 20.12, 13. 5- (1-butyl-3-ethyl-1H-indol-2-yl) picolinic acid (4f). The title compound was prepared from 1f (0.016 mmol) and 1-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (4 mg, 68% 142.08, 138.19, 135.21, 129.05, 127.55, 126.74, 124.06, 120.93, 120.32, 120.25, 110.63, 77.16, 44.35, 32.23, 20.08, 17.93, 16.02, 13.64 5- (1-butyl-3-cyano-1H-indol-2-yl) picolinic acid (4g). The title compound was prepared from 1g (0.023 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as a yellow oil (3.9 mg, 45% 
320.1330.
5-(1-butyl-4-(trifluoromethyl)-1H-indol-2-yl)picolinic acid (4h)
. The title compound was prepared from 1h and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (10 mg, 79%). 
5-(1-butyl-5-chloro-1H-indol-2-yl)picolinic acid (4j)
. The title compound was prepared from 1j (0.015 mmol) and 1-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (2.9 mg, 50% 
5-(1-butyl-6-chloro-1H-indol-2-yl)picolinic acid (4k)
. The title compound was prepared from 1k (0.021 mmol) and 1-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (6.4 mg, 79% 139.94, 138.76, 134.88, 133.98, 131.34, 128.08, 125.44, 123.96, 121.04, 108.27, 104.95, 44.57, 32.35, 20.13, 18.75, 13.69 5- (1-ethyl-4-methoxy-1H-indol-2-yl) picolinic acid (4n). The title compound was prepared from 1n (0.044 mmol) and 1-iodoethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (7 mg, 45% 36, 154.67, 149.13, 140.61, 138.79, 135.13, 133.79, 125.21, 124.71, 119.91, 117.02, 104.49, 102.83, 100.83, 55.57, 39.93, 15 .59.
5-(1-butyl-7-fluoro-1H-indol-2-yl)picolinic acid (4l
5-(1-butyl-4-methyl-1H-indol-2-yl)picolinic acid (4m
ESI-TOF-MS (m/z): [M+H]
+ calc. 297.1234, obs. 297.1182. 40, 155.32, 148.96, 146.28, 140.93, 138.18, 135.62, 134.10, 125.04, 122.82, 122.47, 111.68, 105.69, 96.70, 44.55, 32.55, 20.49, 13.86 5- (1-butyl-6-methoxy-1H-indol-2-yl) picolinic acid (4q). The title compound was prepared from 1o (0.02 mmol) and 1-iodobutane using the standard alkylation procedure to yield the benzyl and t-butyl product as a clear oil (1.8 mg, 51% 26, 157.53, 146.82, 143.57, 139.91, 138.65, 134.45, 134.26, 124.77, 122.56, 122.25, 110.83, 106.02, 94.09, 55.93, 44.38, 32.05, 20.11, 13.73 . ESI-TOF-MS (m/z):
5-(1-butyl-6-hydroxy-1H-indol-2-yl)picolinic acid (4o
5-(1-butyl-6-fluoro-1H-indol-2-yl)picolinic acid (4p)
[M+H] + calc. 325.1547, obs. 325.1500.
5-(1-(cyclopropylmethyl)-3-methyl-1H-indol-2-yl)picolinic (5). The title compound was prepared from 1a
(0.021 mmol) and (bromomethyl)cyclopropane using the standard alkylation/deprotection procedure to yield the product as an orange oil (6 mg, 80%). 87, 145.22, 144.30, 142.08, 138.52, 135.11, 129.78, 128.61, 126.57, 124.20, 120.40, 119.95, 114.71, 110.70, 48.69, 31.07, 11.52, 9.37, 4. 
5-(1-benzyl-1H-indol-2-yl)picolinic acid (6)
. The title compound was prepared from 1a (0.02 mmol) and benzyl bromide using the standard alkylation/deprotection procedure to yield the product as an orange oil (3 mg, 39%). 23, 146.66, 143.68, 139.57, 139.25, 137.21, 135.38, 134.01, 129.35, 128.03, 125.81, 125.02, 124.16, 121.64, 121.32, 115.86, 113.97, 110.83, 106.26, 48. 
5-(1-(3-fluoropropyl)-1H-indol-2-yl)picolinic acid (7)
. The title compound was prepared from 1a (0.016 mmol) and 1-fluoro-3-iodopropane using the standard alkylation/deprotection procedure to yield the product as an orange oil (2.3 mg, 41% 
5-(1-(3-amino-3-oxopropyl)-1H-indol-2-yl)picolinic acid (8).
Compound 1a (11 mg, 0.037 mmol) and 3-bromopropanamide (11 mg, 2 eq) were dissolved in 1 mL MeCN and 0.5 mL THF. 82 mg CsF (adsorbed in a 3:5 ratio to Celite) was added and the reaction mixture was stirred at 90 °C for 18 h. Standard pTLC and TFA deprotection procedures yielded the product as an orange solid (4 mg, 30%). 81, 165.45, 149.51, 146.91, 139.22, 138.96, 137.17, 133.65, 129.25, 124.97, 123.53, 121.78, 121.15, 111.54, 105.66, 41.18, 35.99 .
ESI-TOF-MS (m/z): [M+H]
+ calc. 310.1186, obs. 310.1152.
5-(1-(2-methoxyethyl)-1H-indol-2-yl)picolinic acid (9)
. The title compound was prepared from 1a and 1-bromo-2-methoxyethane using the standard alkylation/deprotection procedure to yield the product as an orange oil (3.3 mg, 31%). 38, 149.81, 146.74, 139.45, 139.37, 24 137.88, 133.86, 129.14, 124.83, 123.39, 121.72, 121.10, 111.56, 105.27, 71.72, 58.91, 44.93, 29. 39, 149.43, 148.01, 144.73, 138.39, 135.53, 132.79, 131.30, 129.25, 129.05, 127.85, 124.53, 123.45, 121.82, 121.11, 119.37, 118.52, 111.59, 105.14, 46.06, 35.75 5- (1-(3-(3-chlorophenyl) propyl)-1H-indol-2-yl)picolinic acid (11). To a solution of 3-(3-chlorophenyl)-propan-1-ol (42 mg, 0.24 mmol) in 1 mL DCM was added PBr 3 (22 μL, 1 eq). After 1 h of stirring the reaction mixture was diluted with 25 mL DCM and washed with 25 mL 1 M aqueous NaOH. The organic layer was dried over MgSO 4 and concentrated. The resulting crude bromide (a clear oil) was directly reacted with 1a using the standard alkylation/deprotection procedure to yield the title compound as an orange oil (1.7 mg, 13% 2H), 7.20 (ddd, J = 7.9, 6.4, 1.5 Hz, 1H), 2H), 6.98 (s, 1H), 1H), 6.76 (s, 1H), 4.20 (t, J = 7.7 Hz, 2H), 2.49 (t, J = 7.2 Hz, 2H), 2.03 (q, J = 7.5 Hz, 2H).
5-(1-(4-chlorophenethyl)-1H-indol-
13
C NMR (151 MHz, CDCl 3 ) δ 164.26, 148.63, 147.11, 142.40, 138.74, 138.67, 135.03, 134.46, 133.88, 129.94, 128.40, 128.16, 126.65, 126.54, 124.70, 123.61, 121.60, 120.94, 110.45, 105.98, 43.51, 32.38, 30. 5- (1-(3-hydroxypropyl)-1H-indol-2-yl) picolinic acid (12). The title compound was prepared from 1a and (3-bromopropoxy)(tert-butyl)dimethylsilane using the standard alkylation procedure to produce the TBS and t-Bu protected product. TBS removal proceeded by stirring the compound with TBAF (10 eq) in 0.5 mL THF for 18 h. After partitioning between water and DCM, the organic layer was dried over MgSO 4 , concentrated and purified by pTLC with 1:2 EtOAc/hexane to afford the free alcohol. Standard TFA deprotection yielded the final product as an orange solid (3.4 mg, 32% 41, 149.54, 147.17, 139.29, 138.72, 137.11, 133.36, 129.23, 124.99, 123.66, 121.96, 121.26, 111.26, 105.88, 66.34, 41.12, 29.16 . ESI-TOF-MS (m/z): 297.1234, obs.297.1235. 5-(1-(4,4,4-trifluorobutyl)-1H-indol-2-yl) picolinic acid (13). The title compound was prepared from 1a (0.023 mmol) and 1,1,1-trifluoro-4-iodobutane using the standard alkylation/deprotection procedure to yield the product as an orange oil (1.6 mg, 17%). 1 H NMR (600 MHz, CDCl 3 ) δ 8. 86 (s, 1H), 8.37 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 1H), 7.21 (t, J = 7.4 Hz, 1H), 6.76 (s, 1H), 4.33 -4.25 (m, 2H), 1.97 -1.88 (m, 4H) . 13 C NMR (151 MHz, CDCl 3 ) δ 164.32, 147.22, 144.63, 139.02, 138.54, 134.96, 133.71, 128.19, 124.84, 124.59 (q, J CF = 278.41 Hz), 123.89, 121.73, 121.19, 110.23, 106.51, 43.07, 30.91 
349.1129.
5- (1-(benzofuran-2-ylmethyl)-1H-indol-2-yl)picolinic acid (14) . To a solution of benzofuran-2-ylmethanol (36 mg, 0.24 mmol) in 1 mL DCM was added PBr 3 (22 μL, 1 eq). After 1 h of stirring the reaction mixture was diluted with 25 mL DCM and washed with 25 mL 1 M aqueous NaOH. The organic layer was dried over 26 MgSO 4 and concentrated. The resulting crude bromide (a clear oil) was directly reacted with 1a using the standard alkylation/deprotection procedure to yield the title compound as an orange oil (2.9 mg, 23% 58, 159.51, 155.81, 149.73, 147.40, 138.81, 132.25, 129.02, 125.27, 124.98, 124.33, 123.87, 123.46, 122.00, 121.87, 121.57, 117.51, 115.62, 111.86, 106.06, 105.45, 99.03, 42.58 5- (1-((4-carbamoyloxazol-2-yl) 20, 162.00, 160.17, 149.26, 147.49, 142.90, 138.72, 137.79, 136.86, 136.49, 127.97, 125.10, 123.41, 121.23, 116.86, 114.93, 110.89, 105.40, 41.33 
5-(1-((4-(methoxycarbonyl)oxazol-2-yl)methyl)-1H-indol-2-yl)picolinic (16). Methyl 2-(chloromethyl)oxazole-
4-carboxylate was hydrolyzed with 3 eq LiOH in 1:5 water/THF over 2 h following acidification with 1 M HCl.
The aqueous solution was then extracted with EtOAc which was then evaporated to quantitatively produce the corresponding carboxylic acid. To a solution of 2-(chloromethyl)oxazole-4-carboxylic acid (27 mg, 0.17 mmol) in 2 mL 1:1 THF/DCM was added oxalyl chloride (16 μL, 1.1 eq) and catalytic (1 μL) DMF at 0 °C. The mixture was stirred for 18 h, warming to rt. The mixture was cooled to 0 °C and 0. To the amide (5 mg, 0.031 mmol) in 0.4 mL THF was added potassium iodide (6.2 mg, 2.4 eq) and the mixture was stirred for 10 min at 50 °C. 1a (9 mg, 0.031 mmol) and 150 mg CsF (adsorbed in a 3:5 ratio to Celite) were added and the reaction was stirred at 75 °C for 18 h. The mixture was filtered and purified by pTLC with 9:1 EtOAc/hexane and deprotected with TFA to yield the title compound as an orange solid (1.7 mg, 13% 3-(1-butyl-4-chloro-1H-indol-2-yl) 23, 140.60, 138.37, 134.73, 133.38, 131.02, 130.01, 129.79, 129.11, 127.00, 126.17, 122.56, 119.80, 108.95, 101.46, 44.38, 32.23, 20.07, 13. 4-(1-butyl-4-chloro-1H-indol-2-yl) 140.69, 138.70, 138.28, 130.66, 129.42, 128.81, 127.05, 126.31, 122.83, 119.91, 109.03, 102.04, 44.49, 32.20, 20 (5- (1-butyl-4-chloro-1H-indol-2-yl) 98, 148.80, 138.40, 137.49, 127.68, 126.20, 122.79, 122.25, 120.92, 120.34, 119.92, 108.94, 101.94, 64.32, 44.41, 32.31, 20.11, 13.76 77, 156.24, 153.47, 149.65, 146.65, 136.83, 135.65, 127.84, 126.62, 125.53, 125.18, 123.86, 123.65, 123.31, 121.60, 121.25, 120.96, 112 96, 155.44, 152.61, 148.83, 147.35, 136.86, 134.33, 128.01, 127.13, 124.73, 124.64, 123.94, 123.47, 123.22, 121.94, 121.38, 120.77 92, 146.25, 143.33, 138.49, 137.75, 136.47, 126.55, 126.39, 125.94, 125.74, 123.47, 121.79, 119.88, 113.25 tert-butyl 5- (1-(tert-butyloxycarbonyl)-indol-3-yl) 31, 149.56, 148.76, 147.90, 136.04, 135.44, 132.92, 128.28, 125.30, 125.05, 124.33, 123.62, 119.52, 118.02, 115.84, 84.69, 82.42, 28.32, 28. 
